ACR CONVERGENCE 2020—Patients with rheumatoid arthritis (RA) and concurrent liver disease or interstitial lung disease (ILD), or with treatment-refractory RA, pose treatment challenges, said panelists in the ACR Convergence 2020 session, How I Treat Difficult RA. Each panelist discussed a difficult case and raised big-picture questions on how to best treat patients facing each challenge….
Search results for: liver
ACR Introduces Draft Guideline for RA Management
Treating RA can be complicated, especially if the patient is suffering from comorbidities. In a session at ACR Convergence 2020, experts discussed the development of a new ACR draft guideline for RA management & how it can be applied in real-life clinical practice.
Anti-TNF Treatment Trial Encouraging for High-Risk APS Pregnancies
Early results in a phase 2 trial are finding that adding a TNF blocker to other treatment could greatly lower the risk of serious complications during pregnancy for women who have antiphospholipid syndrome with lupus anticoagulant.
Optimize Gout Management with the Latest Evidence-Based Guidance
ACR Convergence 2020—In May 2020, the ACR published its updated guideline for the management of gout.1 It followed on the heels of a 2017 gout guideline published by the American College of Physicians.2 Although the guidelines provide similar recommendations on the treatment of acute gout, they differ importantly in the use of uric acid-lowering therapy…
Advantages of Embedding a Specialty Pharmacist in a Rheumatology Clinic
The number of medications with rheumatologic indications has increased in parallel with expanding complexities of medication approval and delivery. Simply starting a patient on a biologic medication or new disease-modifying anti-rheumatic drug (DMARD) can be time consuming and frustrating for physicians, nurses and their support staff. In addition to educating the patient and obtaining prior…
Study: DPP4 Inhibitors Yield Promise for Systemic Sclerosis Treatment
A recent paper in Arthritis & Rheumatology opens up the possibility of a new research avenue to treat systemic sclerosis: dipeptidyl peptidase 4 (DPP4) inhibitors, a previously approved therapy for type 2 diabetes.1 Work in mouse models and on skin samples from systemic sclerosis patients suggests these drugs pose a promising area of future translational…
Yao Syndrome: A Case Report & Clinical Review
Case Presentation History of present illness A 66-year-old white woman presented with unexplained, recurrent episodes of high fever, abdominal pain, rash and arthralgias occurring over the previous three years. During typical episodes, the patient experienced flu-like symptoms, followed by fever, abdominal pain and non-bloody diarrhea without tenesmus. Her temperatures were 101–103ºF, with chills lasting up…
Diversity: From Concepts to Outcomes
ACR CONVERGENCE 2020—In 2020, terms like unconscious bias, diversity and inclusivity are buzzwords in rheumatology, as well as throughout American society. The COVID-19 pandemic revealed stark disparities in healthcare outcomes for rheumatic disease patients of racial and ethnic minorities, including new research that shows Black and Latinx patients have a higher risk of hospitalization and…
Dr. Fauci Talks COVID-19 with the ACR
ACR CONVERGENCE 2020—At the ACR’s fully virtual annual meeting on Saturday, Nov. 7, Anthony S. Fauci, MD, director of the National Institute of Allergy and Infectious Diseases (NIAID) since 1984, delivered a special lecture on COVID-19, from virology to therapy to vaccine development. Novel Coronavirus, Familiar Vectors When Chinese physicians first reported infections by what…
Pediatric Care, Disparity Awareness Among Rheumatology Research Foundation-Funded Studies Underway
Investigators are tackling rheumatology practice challenges, assessing what drives career choices in pediatric rheumatology, improving fellowship training and more—all with the support of the Rheumatology Research Foundation.
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 121
- Next Page »